Last reviewed · How we verify
short postimplantation dual antiplatelet therapy
A treatment regimen that combines two antiplatelet agents for a shortened duration following coronary stent implantation to prevent thrombosis while reducing bleeding risk.
A treatment regimen that combines two antiplatelet agents for a shortened duration following coronary stent implantation to prevent thrombosis while reducing bleeding risk. Used for Prevention of stent thrombosis following coronary stent implantation, Acute coronary syndrome management with percutaneous coronary intervention.
At a glance
| Generic name | short postimplantation dual antiplatelet therapy |
|---|---|
| Sponsor | National Institute of Cardiology, Warsaw, Poland |
| Drug class | Antiplatelet therapy regimen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dual antiplatelet therapy (DAPT) typically combines aspirin with a P2Y12 inhibitor (such as clopidogrel, prasugrel, or ticagrelor) to prevent stent thrombosis by inhibiting platelet aggregation through different pathways. Short postimplantation DAPT refers to a reduced-duration regimen (typically 1-3 months) rather than the standard 12 months, balancing the need for thrombotic protection against the increased bleeding risk associated with prolonged dual therapy.
Approved indications
- Prevention of stent thrombosis following coronary stent implantation
- Acute coronary syndrome management with percutaneous coronary intervention
Common side effects
- Bleeding (major and minor)
- Stent thrombosis
- Gastrointestinal bleeding
Key clinical trials
- Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients (PHASE4)
- Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: